Home  /   Products  /   Anti-cold  /   Oxymetazoline (Oxyfrin) nasal spray dosed 22.5 mcg/dose 280 doses – [15 ml vial]

Oxymetazoline (Oxyfrin) nasal spray dosed 22.5 mcg/dose 280 doses – [15 ml vial]


Vasoconstrictor drug for local use in ent practice

SKU: 62292 Category:


Oxyfrine Pharmacodynamics
Oxymetazoline belongs to the group of alpha-adrenergic stimulants for local use. It has a vasoconstrictor effect. When administered intranasally it reduces swelling of the mucous membrane of the upper airways and nasal secretions. Restores nasal breathing.
Elimination of nasal cavity mucous membrane edema helps restore aeration of paranasal sinuses, middle ear cavity, which reduces the likelihood of bacterial complications (maxillary sinusitis, sinusitis, otitis media).
During local intranasal application and therapeutic concentrations it does not irritate and does not cause nasal mucosal hyperemia.
Oxymetazoline begins to act quickly, within minutes. Its duration of action is up to 12 hours.

– Treatment of acute respiratory diseases accompanied by a runny nose;
– allergic rhinitis;
– vasomotor rhinitis;
– Restoration of drainage in inflammation of paranasal sinuses, eustachitis, otitis media;
– To eliminate swelling before diagnostic manipulations in the nasal passages.

Contraindications .
– Hypersensitivity to the drug;
– Atrophic (dry) rhinitis;
– closed-angle glaucoma;
– condition after transsphenoidal hypophysectomy, surgical interventions on the dura mater (in anamnesis).
In patients with diseases of the cardiovascular system (arterial hypertension, coronary heart disease, chronic heart failure, marked atherosclerosis, tachycardia, arrhythmias), carbohydrate metabolism disorders (diabetes), thyroid function disorders (hyperthyroidism), pheochromocytoma, chronic renal insufficiency, prostatic hyperplasia with clinical symptoms (urinary retention), increased intraocular pressure, porphyria, and in patients taking monoamine oxidase inhibitors during the previous 2 weeks and within 2 weeks after their withdrawal, tricyclic antidepressants, bromocriptine.
Pregnancy and lactation:
When used during pregnancy or breastfeeding, the recommended dose should not be exceeded. The drug may be used only in cases when the potential benefit to the mother exceeds the potential risk to the fetus and child.

Directions for use and dosages

  • Intranasal.
  • Children aged 1 to 6 years: 1 injection of Oxyfrin, nasal spray dosed 11.25 mcg/dose into each nostril 2-3 times a day. The drug is used for 5 to 7 days. The drug may be administered again only after several days.
  • Adults and children over 6 years of age: 1 injection of Oxyfrin, nasal spray dosed 22.5 µg/dose into each nostril 2-3 times a day.
  • If symptoms worsen or do not improve within 3 days, consult a physician. Use in the recommended dose without consulting a physician for no more than 7 days.
  • Doses higher than recommended may be used only under the supervision of a physician.
    With frequent and prolonged use of the drug, nasal congestion may reappear or worsen.
  • If these symptoms occur, discontinue treatment and consult a physician.
  • One 45 µl injection contains:
    – 11.25 µg oxymetazoline hydrochloride – for Oxyfrin, nasal spray dosed 11.25 µg/dose;
    – 22.5 µg oxymetazoline hydrochloride – for Oxyfrine, nasal spray dosage 22.5 µg/dose.